 |
11 Diseases |  |
3 Trials |
|
3 Trials |  |
96 News |  |
| 12» |
- macozinone (PBTZ169) / Innovative Medicines for Tuberculosis, Nearmedic, Bill & Melinda Gates Foundation, Sutezolid (PNU-100480) / Sequella
Efficacy of Macozinone and Sutezolid against Mycobacterium leprae (Convention Center - Hall I-1 (1st Floor); In-Person-Only) - Oct 11, 2024 - Abstract #ASTMH2024ASTMH_2195;
Results & Conclusion Results show that Macozinone and Sutezolid are effective against M. lepra e both in vitro (axenic and intracellular) and in vivo (MFP). Therefore, Macozinone and Sutezolid, having different modes of action, should be tested in combination with other first and second line drugs to explore new shorter treatment regimens for leprosy.
- || Trial completion date, Trial primary completion date: Efficacy and Safety Evaluation of Two to Four Months of Treatment With the Combination Regimens of DBOS and PBOS in Adults With Pulmonary Tuberculosis (clinicaltrials.gov) - Oct 1, 2024
P2, N=514, Active, not recruiting, Sponsor: Bill & Melinda Gates Medical Research Institute
Therefore, Macozinone and Sutezolid, having different modes of action, should be tested in combination with other first and second line drugs to explore new shorter treatment regimens for leprosy. Trial completion date: Oct 2024 --> Jan 2025 | Trial primary completion date: Oct 2024 --> Jan 2025
- | Preclinical, Journal: Investigating the treatment shortening potential of a combination of bedaquiline, delamanid and moxifloxacin with and without sutezolid, in a murine tuberculosis model with confirmed drug exposures. (Pubmed Central) - Sep 30, 2024
BDM-based regimens, with and without sutezolid, have a higher efficacy than the HRZE regimen in the BALB/c model of TB, with some improvement by adding sutezolid. By translating these results to TB patients, this novel BDMU regimen should be able to reduce treatment duration by 25% compared to HRZE therapy.
- ||| Enrollment closed, Trial completion date, Trial primary completion date: Efficacy and Safety Evaluation of Two to Four Months of Treatment With the Combination Regimens of DBOS and PBOS in Adults With Pulmonary Tuberculosis (clinicaltrials.gov) - Aug 9, 2024
P2, N=514, Active, not recruiting, Sponsor: Bill & Melinda Gates Medical Research Institute
By translating these results to TB patients, this novel BDMU regimen should be able to reduce treatment duration by 25% compared to HRZE therapy. Recruiting --> Active, not recruiting | Trial completion date: Oct 2027 --> Oct 2024 | Trial primary completion date: Oct 2027 --> Oct 2024
- || Review, Journal: New Oxazolidinones for Tuberculosis: Are Novel Treatments on the Horizon? (Pubmed Central) - Jun 27, 2024
Sutezolid, tedizolid, delpazolid and TBI-223 displayed promising preliminary results. Further clinical studies would be required to assess the safety profiles and optimize the dosing regimens.
- || Trial completion date, Trial primary completion date: Efficacy and Safety Evaluation of Two to Four Months of Treatment With the Combination Regimens of DBOS and PBOS in Adults With Pulmonary Tuberculosis (clinicaltrials.gov) - May 8, 2024
P2, N=514, Recruiting, Sponsor: Bill & Melinda Gates Medical Research Institute
Further clinical studies would be required to assess the safety profiles and optimize the dosing regimens. Trial completion date: Mar 2027 --> Oct 2027 | Trial primary completion date: Mar 2027 --> Oct 2027
- | Sutezolid (PNU-100480) / Sequella
Journal: A Tandem Ring Closure and Nitrobenzene Reduction with Sulfide Provides an Improved Route to an Important Intermediate for the Anti-Tuberculosis Drug Candidate Sutezolid. (Pubmed Central) - Apr 25, 2024
Initial demonstrations of the full 3-step strategy were successfully conducted on scales up to 100 g with overall yields of 53-68%. This preliminary work will serve as the foundation for a broader low-cost redesign of the sutezolid synthetic process.
- | Phase classification: Efficacy and Safety Evaluation of Two to Four Months of Treatment With the Combination Regimens of DBOS and PBOS in Adults With Pulmonary Tuberculosis (clinicaltrials.gov) - Dec 8, 2023
P2, N=514, Recruiting, Sponsor: Bill & Melinda Gates Medical Research Institute
This preliminary work will serve as the foundation for a broader low-cost redesign of the sutezolid synthetic process. Phase classification: P2b --> P2
- | Phase classification: PanACEA - STEP2C -01 (clinicaltrials.gov) - Dec 1, 2023
P2, N=360, Recruiting, Sponsor: Michael Hoelscher
Phase classification: P2b --> P2 Phase classification: P2b --> P2
- Dynamic PET facilitated Modeling and Novel Antibiotic Regimens for Tuberculous Meningitis due to Multidrug-Resistant Strains (204 AB) - Sep 6, 2023 - Abstract #IDWeek2023IDWeek_1812;
- |||| Enrollment open: Efficacy and Safety Evaluation of Two to Four Months of Treatment With the Combination Regimens of DBOS and PBOS in Adults With Pulmonary Tuberculosis (clinicaltrials.gov) - Aug 18, 2023
P2b, N=514, Recruiting, Sponsor: Bill & Melinda Gates Medical Research Institute
Phase classification: P2b --> P2 Not yet recruiting --> Recruiting
- |||||| pretomanid (PA-824) / Global Alliance for TB Drug Development, Sirturo (bedaquiline) / J&J, Pharmstandard, Sutezolid (PNU-100480) / Sequella
Enrollment open, Trial initiation date: panTB-HM: A Pan-TB Regimen Targeting Host and Microbe (clinicaltrials.gov) - Aug 16, 2023
P2/3, N=352, Recruiting, Sponsor: The Aurum Institute NPC
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: Jan 2023 --> Jul 2023
- |||||| New P2 trial, New P2b trial: Efficacy and Safety Evaluation of Two to Four Months of Treatment With the Combination Regimens of DBOS and PBOS in Adults With Pulmonary Tuberculosis (clinicaltrials.gov) - Aug 2, 2023
P2b, N=514, Not yet recruiting, Sponsor: Bill & Melinda Gates Medical Research Institute
- || Sivextro (tedizolid) / Merck (MSD), Nabriva Therap, Sutezolid (PNU-100480) / Sequella
Review, Journal: Analytical Methodologies for the Estimation of Oxazolidinone Antibiotics as Key Members of anti-MRSA Arsenal: A Decade in Review. (Pubmed Central) - Jun 28, 2023
The review comprises six sections (one for each drug) with their related tables that depict critical figures of merit and some experimental conditions for the reviewed methods. Furthermore, future perspectives about the analytical methodologies that can be developed in the near future for determination of these drugs are suggested.
- | pretomanid (PA-824) / Global Alliance for TB Drug Development, nitroimidazole (TBA-354) / Global Alliance for TB Drug Development, Sutezolid (PNU-100480) / Sequella
Journal: Inhaled Adjunct Therapy with Second-Line Drug Candidates for Dose Reduction in Chemotherapeutic Regimens for Multi-drug-Resistant Tuberculosis. (Pubmed Central) - Jun 12, 2023
We prepared dry powder inhalation (DPI) formulations comprising sutezolid (SUT), the second-generation pretomanid analog TBA-354 (TBA), or a fluorinated derivative of TBA-354 (32,625) in a matrix of the biodegradable polymer poly(L-lactide). The addition of 0.25-0.5
- ||| Trial completion, Combination therapy: SUDOCU: PanACEA Sutezolid Dose-finding and Combination Evaluation (clinicaltrials.gov) - May 1, 2023
P2b, N=75, Completed, Sponsor: Michael Hoelscher
The addition of 0.25-0.5 Active, not recruiting --> Completed
- | Enrollment open: PanACEA - STEP2C -01 (clinicaltrials.gov) - Apr 18, 2023
P2b, N=360, Recruiting, Sponsor: Michael Hoelscher
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | New P2b trial: PanACEA - STEP2C -01 (clinicaltrials.gov) - Apr 11, 2023
P2b, N=360, Not yet recruiting, Sponsor: Michael Hoelscher
- | Baxdela (delafloxacin) / Menarini, Melinta Therap, Sutezolid (PNU-100480) / Sequella
Journal: Assessment of Lipophilicity Parameters of Antimicrobial and Immunosuppressive Compounds. (Pubmed Central) - Mar 30, 2023
The presented results demonstrate that RP-TLC method may be a good tool in determining the lipophilic properties of studied substances. Obtained lipophilic parameters of the compounds can be valuable in the design of their new derivatives as efficient antimicrobial and immunosuppressive agents.
- | rifampicin / Generic mfg., Sutezolid (PNU-100480) / Sequella
Journal: Adaptation to the intracellular environment of primary human macrophages influences drug susceptibility of Mycobacterium tuberculosis. (Pubmed Central) - Mar 14, 2023
We observed that hypoxia induced greater lipid body formation and no additional shifts in drug tolerance, suggesting that the adaptation of intracellular Mtb to baseline host cell conditions under normoxia dominates changes to intracellular drug susceptibility. Using unbound plasma concentrations in patients as surrogates for free drug concentrations in lung interstitial fluid, we estimate that intramacrophage Mtb in granulomas are exposed to bacteriostatic concentrations of most study drugs.
- Increasing access to the next generation of life-saving tuberculosis medications through techno-economically guided synthetic process improvements (Room 202 (Indiana Convention Center)) - Feb 14, 2023 - Abstract #ACSSp2023ACS_SP_8411;
The synthetic improvements are focused on optimizing for cost and manufacturability, rather than applying a more traditional academic approach of focusing on publication impact and novelty. These improvements to the overall TB regimen may improve access to the overall regimen by removing key cost-drivers, supply constraints, or manufacturing bottlenecks that plagued the previously disclosed routes.
- Sutezolid (PNU-100480) / Sequella
PanACEA SUDOCU COMBINATION DOSE-FINDING TRIAL SHOWS SUTEZOLID IS A SAFE OXAZOLIDINONE (Ballroom 1 (Level 5)) - Feb 13, 2023 - Abstract #CROI2023CROI_124;
- | Sirturo (bedaquiline) / J&J, Pharmstandard
Journal: Antimicrobial Effect of Oxazolidinones and Its Synergistic Effect with Bedaquiline Against Mycobacterium abscessus Complex. (Pubmed Central) - Jan 24, 2023
TZD exhibited stronger antimicrobial efficacy against MABC isolates as compared to efficacies of DZD, SZD, and LZD. Importantly, MICs of oxazolidinones were markedly decreased when they were combined with BDQ, thus suggesting that combinations of BDQ and oxazolidinones may be effective treatments for MABC infections.
- |||||||||| pretomanid (PA-824) / Global Alliance for TB Drug Development, Sirturo (bedaquiline) / J&J, Pharmstandard, Sutezolid (PNU-100480) / Sequella
New P2/3 trial: panTB-HM: A Pan-TB Regimen Targeting Host and Microbe (clinicaltrials.gov) - Jan 17, 2023
P2/3, N=352, Not yet recruiting, Sponsor: The Aurum Institute NPC
- || rifampicin / Generic mfg.
Review, Journal: Annual progress of chemotherapy of multidrug/rifampicin-resistant tuberculosis in 2022 (Pubmed Central) - Jan 10, 2023
Meanwhile, different new chemotherapy regimens centered on new drugs have been explored in-depth by international scholars. In this article, we reviewed the progress of chemotherapy of multidrug/rifampicin-resistant tuberculosis from October 2021 to September.
- | Sivextro (tedizolid) / Merck (MSD), Nabriva Therap, delpazolid (LCB01-0371) / LegoChem Biosci, Sutezolid (PNU-100480) / Sequella
Preclinical, Journal: Novel oxazolidinones harbor potent in vitro activity against the clinical isolates of multidrug-resistant Mycobacterium tuberculosis in China. (Pubmed Central) - Dec 17, 2022
Different oxazolidinones can have discrepant antimicrobial activity against different mycobacterial species, or have different manifestations out of cell or in cell. Understanding these differences would be helpful in choosing the appropriate drug in clinical practice.
- || Review, Journal: The Struggle to End a Millennia-Long Pandemic: Novel Candidate and Repurposed Drugs for the Treatment of Tuberculosis. (Pubmed Central) - Dec 9, 2022
We describe new diaryloquinolines in development, striving to build on the immense success of bedaquiline. Finally, we discuss some of these compounds that have shown encouraging additive or synergistic benefit when used in combination, providing some promise for the future in treating this ancient scourge.
- || SQ-109 / Sequella
Review, Journal: MmpL3 Inhibition as a Promising Approach to Develop Novel Therapies against Tuberculosis: A Spotlight on SQ109, Clinical Studies, and Patents Literature. (Pubmed Central) - Nov 16, 2022
SQ109 has demonstrated activity against drug-sensitive (DS) and drug-resistant (DR) Mycobacterium tuberculosis (Mtb) and a synergistic effect with isoniazid (INH), rifampicin (RIF), clofazimine (CFZ), and bedaquiline (BNQ)...The combinations of SQ109 with other anti-TB drugs (chloroquine, hydroxychloroquine, and sutezolid) have also been claimed in the patent literature...Developing MmpL3 inhibitors is a promising approach to fighting the challenges associated with DS-TB and DR-TB. The authors foresee MmpL3 inhibitors such as SQ109 as future drugs for TB treatment.
- | Journal: A battery of tandem mass spectrometry assays with stable isotope-dilution for the quantification of 15 anti-tuberculosis drugs and two metabolites in patients with susceptible-, multidrug-resistant- and extensively drug-resistant tuberculosis. (Pubmed Central) - Nov 9, 2022
The authors foresee MmpL3 inhibitors such as SQ109 as future drugs for TB treatment. Such convenient extraction methods and the use of stable isotope-labelled drugs as internal standards provide an accurate and precise quantification of plasma concentrations of all major clinically-used antiTB drugs regimens and is optimally suited for clinically efficient TDM against tuberculosis.
- || Trial primary completion date, Combination therapy: SUDOCU: PanACEA Sutezolid Dose-finding and Combination Evaluation (clinicaltrials.gov) - Aug 11, 2022
P2b, N=75, Active, not recruiting, Sponsor: Michael Hoelscher
Such convenient extraction methods and the use of stable isotope-labelled drugs as internal standards provide an accurate and precise quantification of plasma concentrations of all major clinically-used antiTB drugs regimens and is optimally suited for clinically efficient TDM against tuberculosis. Trial primary completion date: Apr 2022 --> Oct 2022
- | Journal: Discovery and Development of Antibacterial Agents: Fortuitous and Designed. (Pubmed Central) - May 26, 2022
This article aims to review the investigational and recently approved antibacterials with a focus on their structure, mechanisms of action/resistance, and spectrum of activity. Delving deep, their success or otherwise in various phases of clinical trials is also discussed while attributing the same to various causal factors.
- || Sutezolid (PNU-100480) / Sequella
PK/PD data, Journal: Single Ascending-Dose Study To Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid in Healthy Adult Subjects. (Pubmed Central) - Apr 22, 2022
Maximum concentration (C) of sutezolid, PNU-101603, and PNU-101244 increased in a less-than-proportional manner with an increase in sutezolid dose between 300 mg and 1,800 mg. Total exposure (AUC [area under the concentration-time curve from time zero to the time of the last quantifiable concentration] and AUC [area under the plasma concentration time curve from time zero extrapolated to infinity]) of sutezolid, PNU-101603, and PNU-101244 increased proportionally with an increase in sutezolid dose.
- || Enrollment closed, Combination therapy: SUDOCU: PanACEA Sutezolid Dose-finding and Combination Evaluation (clinicaltrials.gov) - Feb 21, 2022
P2b, N=75, Active, not recruiting, Sponsor: Michael Hoelscher
Total exposure (AUC [area under the concentration-time curve from time zero to the time of the last quantifiable concentration] and AUC [area under the plasma concentration time curve from time zero extrapolated to infinity]) of sutezolid, PNU-101603, and PNU-101244 increased proportionally with an increase in sutezolid dose. Recruiting --> Active, not recruiting
- | rifampicin / Generic mfg.
Journal: Exploring targets of cell wall protein synthesis and overexpression mediated drug resistance for the discovery of potential M. tb inhibitors. (Pubmed Central) - Feb 8, 2022
The early detection of mycobacterium tuberculosis can be permanently cured by DOTS comprising Pyrazinamide (Z), Isoniazid (H), Rifampin (R) and Ethambutol (E)...Overexpression of these genes may produce drug-resistant due to dose misuse or the intake of quality compromised anti tubercular drug regimen. Therefore, in the present review there has been a necessity to report the second line antitubercular chemotherapeutics to target various proteins which are the building block of M. tb cell wall, overexpression of which may produce drug resistance.
- || Trial completion date, Trial primary completion date, Combination therapy: SUDOCU: PanACEA Sutezolid Dose-finding and Combination Evaluation (clinicaltrials.gov) - Feb 8, 2022
P2b, N=75, Recruiting, Sponsor: Michael Hoelscher
Therefore, in the present review there has been a necessity to report the second line antitubercular chemotherapeutics to target various proteins which are the building block of M. tb cell wall, overexpression of which may produce drug resistance. Trial completion date: Dec 2021 --> Aug 2022 | Trial primary completion date: Nov 2021 --> Apr 2022
- || Review, Journal: The pipeline of new molecules and regimens against drug-resistant tuberculosis. (Pubmed Central) - Nov 25, 2021
Compounds with novel targets involved in diverse bacterial functions such as cell wall synthesis (DrpE1, MmpL3), electron transport, DNA synthesis (GyrB), cholesterol metabolism and transcriptional regulation of ethionamide bioactivation pathways have advanced to early clinical studies with the potential to enhance antibacterial activity when added to new or established anti-TB drug regimens. Clinical validation of preclinical in vitro and animal model predictions of new anti-TB regimens may further improve the translational value of these models to identify optimal anti-TB therapies.
- | Sivextro (tedizolid) / Merck (MSD), Nabriva Therap, delpazolid (LCB01-0371) / LegoChem Biosci, Sutezolid (PNU-100480) / Sequella
Preclinical, Journal: In vitro Antimicrobial Activity Comparison of Linezolid, Tedizolid, Sutezolid and Delpazolid Against Slowly Growing Mycobacteria Isolated in Beijing, China. (Pubmed Central) - Nov 22, 2021
According to the multiple sequence alignment, novel 23srRNA mutations (A2267C and A2266G) in M. intracellulare and rplD mutations (Thr147Ala) in M. avium were identified in this study which have plausible involvement in rendering resistance against linezolid. This study showed that sutezolid harbors the strongest inhibitory activity against M. intracellulare, M. avium and M. kansasii in vitro, which provided important insights on the potential clinical application of oxazolidinones for treating SGM infections.
- || Review, Journal: Oxazolidinone Antibiotics: Chemical, Biological and Analytical Aspects. (Pubmed Central) - Sep 19, 2021
Finally, the most employed analytical techniques for oxazolidinone determination in different matrices, such as biological fluids, tissues, drugs and natural waters, are reviewed. Most are based on HPLC (High Performance Liquid Chromatography) coupled with UV-Vis or mass spectrometer detectors, but, to a lesser extent are also based on spectrofluorimetry or voltammetry.
- | Sivextro (tedizolid) / Merck (MSD), delpazolid (LCB01-0371) / LegoChem Biosci, Sutezolid (PNU-100480) / Sequella
Preclinical, Journal: In Vitro activity comparison of linezolid, tedizolid, sutezolid and delpazolid against rapid growing Mycobacteria isolated in Beijing, China. (Pubmed Central) - Sep 2, 2021
Tedizolid had the strongest inhibitory activity against M. abscessus in vitro, while delpazolid presented the best inhibitory activity against M. fortuitum. This provides important insights into the potential clinical application of oxazolidinones to treat RGM infections.
- | Sivextro (tedizolid) / Merck (MSD), Sutezolid (PNU-100480) / Sequella
Journal: Explanation of the Formation of Complexes between Representatives of Oxazolidinones and HDAS-β-CD Using Molecular Modeling as a Complementary Technique to cEKC and NMR. (Pubmed Central) - Aug 8, 2021
By changing the dielectric constant in the MM/PBSA and MM/GBSA calculations, the effect of changing the solution to methanol/acetonitrile was investigated. A fairly successful attempt was made to predict the chiral separation of the oxazolidinones using the modified cyclodextrin by computational methods.
- | Lamprene (clofazimine) / Novartis
Review, Journal: An overview of new antitubercular drugs, drug candidates, and their targets. (Pubmed Central) - Jul 9, 2021
The last 10 years have made sudden progress giving some new and highly promising drugs including bedaquiline, delamanid, and pretomanid...These targets are either involved in cell wall biosynthesis, protein synthesis, DNA/RNA synthesis, or metabolism. This review discusses recent progress in the discovery of newly developed and Food and Drug Administration approved drugs as well as repurposed drugs, their targets, mode of action, drug-target interactions, and their structure-activity relationship.
- | delpazolid (LCB01-0371) / LegoChem Biosci, Sutezolid (PNU-100480) / Sequella
Preclinical, Journal: In Vitro Activity of Oxazolidinone against Nontuberculous Mycobacteria, Including Macrolide-Resistant Clinical Isolates. (Pubmed Central) - Jun 30, 2021
However, for M. abscessus, M. massiliense, the MIC and MBC values for all oxazolidinone antibiotics showed similar values. Oxazolidinone antibiotics warrant further investigation as potential antibiotics.
- || Sivextro (tedizolid) / Merck (MSD), Sutezolid (PNU-100480) / Sequella
PK/PD data, Journal: Pharmacokinetics of tedizolid, sutezolid, and sutezolid-M1 in non-human primates. (Pubmed Central) - Jun 22, 2021
Once allometrically scaled to humans with a fixed exponent of 0.75 for apparent clearance and 1 for apparent volume of distribution, the AUCs of tedizolid and sutezolid were predicted reasonably well, whereas C was under-predicted for sutezolid. Both NHP and humanized concentration-time profiles will now be used in in vitro hollow-fiber pharmacodynamic experiments to determine if differences in drug exposures result in differences in Mycobacterium tuberculosis kill and emergence of resistance.
- Sutezolid (PNU-100480) / Sequella
[VIRTUAL] Alternative Physical Activity And Health Promotion Concepts Of German Sports Clubs During The First Covid-19 Lockdown () - May 29, 2021 - Abstract #ACSM2021ACSM_839;
In light of the dynamic development of the Corona pandemic, sports clubs must be prepared to offer alternatives to in-person courses also on the middle term. These efforts should be supported by sports organisations and communities.
- clarithromycin / Generic mfg.
[VIRTUAL] Pathogen Box screening identifies novel antimicrobial agents that target Mycobacterium chimaera () - May 20, 2021 - Abstract #ECCMID2021ECCMID_4086;
chimaera that could lead promising new antimicrobials with further drug development . As well as identifying new compounds, we have identified the currently licensed antimicrobial doxycycline as showing efficacy against M .
- ||| Enrollment open, Combination therapy: SUDOCU: PanACEA Sutezolid Dose-finding and Combination Evaluation (clinicaltrials.gov) - May 9, 2021
P2b, N=75, Recruiting, Sponsor: Michael Hoelscher
As well as identifying new compounds, we have identified the currently licensed antimicrobial doxycycline as showing efficacy against M . Not yet recruiting --> Recruiting
- || Sutezolid (PNU-100480) / Sequella
Clinical, Journal: The Discovery of a Conformationally Constrained Oxazolidinone with Improved Safety and Efficacy Profiles for the Treatment of Multidrug-Resistant Tuberculosis. (Pubmed Central) - Dec 16, 2020
Compound 19c displayed superior in vivo efficacy in a mouse TB infection model compared to linezolid and sutezolid...Compound 19c demonstrated an excellent safety profile in a battery of safety assays, including mitochondrial protein synthesis, hERG K, hCav1.2 and Nav1.5 channel, monoamine oxidase, and genotoxicity. In a 4-week repeated dose toxicology study in rats, 19c appeared to have less bone marrow suppression than linezolid, which has been a major liability of the oxazolidinone class.
- || Trial completion date, Trial primary completion date, Combination therapy: SUDOCU: PanACEA Sutezolid Dose-finding and Combination Evaluation (clinicaltrials.gov) - Nov 25, 2020
P2b, N=75, Not yet recruiting, Sponsor: Michael Hoelscher
In a 4-week repeated dose toxicology study in rats, 19c appeared to have less bone marrow suppression than linezolid, which has been a major liability of the oxazolidinone class. Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Dec 2020 --> Nov 2021
- | rifampicin / Generic mfg., Alinia (nitazoxanide) / Lupin, Romark Lab
Journal: The combination rifampin-nitazoxanide, but not rifampin-isoniazid-pyrazinamide-ethambutol, kills dormant Mycobacterium tuberculosis in hypoxia at neutral pH. (Pubmed Central) - May 19, 2020
As shown by lack of regrowth in MGIT, rifampin-nitazoxanide containing combinations, but not R-I-Z-E, killed dormant cells in 28-35 days. These observations might be important in designing new tuberculosis therapies.
- | clarithromycin / Generic mfg., rifampicin / Generic mfg.
Preclinical, Journal, Combination therapy: Oxazolidinones Can Replace Clarithromycin in Combination with Rifampin in a Mouse Model of Buruli Ulcer. (Pubmed Central) - Feb 22, 2020
We conclude that SZD and LZD warrant consideration as alternative companion agents to CLR in combination with RIF to treat BU, especially when CLR is contraindicated, intolerable, or unavailable. Further evaluation could prove SZD superior to CLR in this combination.